(S)-[(2-morpholin-4-yl-ethylcarbamoyl)phenylmethyl]carbamic acid benzyl ester | 1541203-66-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-[(2-morpholin-4-yl-ethylcarbamoyl)phenylmethyl]carbamic acid benzyl ester
• 英文别名: benzyl N-[(1S)-2-(2-morpholin-4-ylethylamino)-2-oxo-1-phenylethyl]carbamate
• CAS: 1541203-66-0
• 化学式: C₂₂H₂₇N₃O₄
• 分子量: 397.474
• InChiKey: HFDYJZVMFXEVRH-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29.0
• 可旋转键数：
  8.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  79.9
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (S)-[(2-morpholin-4-yl-ethylcarbamoyl)phenylmethyl]carbamic acid benzyl ester 在 10 wt% Pd(OH)2 on carbon 、 氢气 、 N,N-二异丙基乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 34.0h， 生成 (S)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[(2-morpholin-4-yl-ethylcarbamoyl)phenylmethyl]-isobutyramide
  参考文献：
  名称：

  Design and synthesis of potential dual NK1/NK3 receptor antagonists

  摘要：

  The tachykinin NK1 and NK3 receptors are a novel drug target for schizophrenia in order to treat not only the positive and cognitive symptoms, but also the associated co-morbid depression and sleep disturbances associated with the disease. A novel class of peptidomimetic derivatives based on a versatile phenylglycine central core was synthesized and tested in vitro as dual NK1/NK3 receptor antagonists. From this series emerged compounds with good NK1 receptor affinity, although only modest dual NK1/NK3 receptor affinity was observed with one of these analogs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.033
• 作为产物：
  描述：

  N-(2-氨基乙基)吗啉 、 Cbz-L-苯甘氨酸 在 N,N-二异丙基乙胺 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 二氯甲烷 为溶剂， 反应 20.08h， 以54%的产率得到(S)-[(2-morpholin-4-yl-ethylcarbamoyl)phenylmethyl]carbamic acid benzyl ester
  参考文献：
  名称：

  Design and synthesis of potential dual NK1/NK3 receptor antagonists

  摘要：

  The tachykinin NK1 and NK3 receptors are a novel drug target for schizophrenia in order to treat not only the positive and cognitive symptoms, but also the associated co-morbid depression and sleep disturbances associated with the disease. A novel class of peptidomimetic derivatives based on a versatile phenylglycine central core was synthesized and tested in vitro as dual NK1/NK3 receptor antagonists. From this series emerged compounds with good NK1 receptor affinity, although only modest dual NK1/NK3 receptor affinity was observed with one of these analogs. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.033